Standard BioTools Inc. LAB
0.74
0.00
0.00%
as of 25 Sep
- Market cap
- $291.7M
- P/E
- 3.4×
Follow LAB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.85%) | (16.72%) | 15.40% | 17.61% | |
| (21.00%) | (12.69%) | 12.83% | 14.34% | ||
ROIC |
(29.24%) | (29.07%) | (56.34%) | (93.89%) | |
Return on Tangible Assets |
(33.29%) | (20.51%) | 15.76% | 17.86% | |
Average Days of Receivables |
79.14 | 57.45 | 176.19 | 67.94 | |
Free Cash Flow per Share |
(0.26) | (0.22) | (0.24) | (0.21) | |
Free Cash Flow |
(98.42) | (82.65) | (94.48) | (82.58) | |
Capital Expenditures |
(11.21) | (8.30) | (3.82) | (2.28) | |
Piotroski F-Score |
3.00 | 3.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(14.66%) | (12.14%) | (8.92%) | (7.90%) | |
Accounts Receivable Turnover |
2.56 | 6.06 | 2.24 | 5.57 | |
Accounts Payable Turnover |
3.77 | 8.18 | 4.39 | 4.96 | |
Inventory Turnover |
0.97 | 2.10 | 1.43 | 2.03 | |
Average Days of Payables |
73.06 | 46.12 | 67.26 | 83.25 | |
Days of Inventory on Hand |
280.54 | 170.45 | 156.19 | 149.03 | |
Tax Rate |
(0.02) | (0.39) | (0.43) | (0.41) | |
Research and Development Expense of Revenue |
26.73% | 30.45% | 26.28% | 21.77% | |
Selling, General and Administrative Expense of Revenue |
146.27% | 128.75% | 114.36% | 102.75% | |
Share Based Compensation of Revenue |
50.20% | 34.70% | 34.12% | 32.02% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.99 | (1.16) | (0.95) | |
Depreciation/Fixed assets |
0.50 | 0.43 | 0.34 | 0.17 | |
Capex/Depreciation |
(1.09) | (1.00) | (0.66) | (0.88) | |
Revenue per Share |
0.16 | 0.22 | 0.22 | 0.22 | |
Operating CF per Share |
(0.23) | (0.19) | (0.23) | (0.21) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.18 | 0.10 | 0.04 | 0.03 | |
Net Profit Margin |
(205.44%) | (87.77%) | 90.67% | 100.37% |
Columns are period end dates